Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Phase 1

• Conditions: Multiple Myeloma; Diffuse Large B Cell Lymphoma in Relapse; Other B Cell Lymphoma in Relapse; Plasma Cell Leukemia; Multiple Myeloma in Relapse; Mantle Cell Lymphoma in Relapse
• Interventions: Biological: SNS01-T

• Registration Number: NCT01435720
• Lead Sponsor: Senesco Technologies, Inc.

Brief Summary

The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.

Detailed Description

The main purpose is to test the safety and tolerability of SNS01-T. The first group of patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B cell lymphoma will be given a relatively low dose. If tolerated, a second group will receive a higher dose. If tolerated by the second group, a third and then a fourth group will receive higher doses. Treatment-related adverse events (side effects), changes in vital signs, physical examination, and laboratory values will be monitored. Patients will receive twice weekly infusions for 6 weeks and then will be followed monthly for 6 months. A secondary purpose is to explore whether SNS01-T is an effective treatment for multiple myeloma, B cell lymphoma and plasma cell leukemia.

Study Timeline

• Study Start: 2011-09
• Study First Submitted: 2011-09-14
• Study First Submitted QC: 2011-09-16
• Study First Posted: 2011-09-19
• Status Verified: 2014-09
• Last Update Submitted: 2014-09-09
• Last Update Posted: 2014-09-11
• Primary Completion: 2014-10
• Study Completion: 2014-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. B cell lymphoma patients must have had their diagnosis confirmed histologically. Plasma cell leukemia (PCL) patients must have peripheral clonal plasma cells >20% of peripheral WBC and >2 x 109/L. Multiple myeloma and PCL patients must have been diagnosed by having met all three of the following IMWG criteria:

   • Clonal bone marrow plasma cells >10%

   • Presence of serum and/or urinary M-protein or, if absent, kappa or lambda serum FLC must be > 10 mg/dl accompanied by an abnormal kappa to lambda ratio (<0.26 or >1.65)

   • Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically, one or more of the following:

     • Hypercalcemia: serum calcium >11.5 mg/100 mL
     • Renal insufficiency: serum creatinine >2mg/dL
     • Anemia: normochromic, normocytic with a hemoglobin value >2 g/100 mL below the lower limit of normal or a hemoglobin value <10 g/100 mL
     • Bone lesions: lytic lesions, severe osteopenia, or pathologic fractures

2. B cell lymphoma patients must have measurable disease defined as at least one lesion that can be accurately measured for response in at least two perpendicular dimensions. Multiple myeloma patients must have measurable disease defined by the following:

   • Serum M-protein ≥0.5g/dL or urine M-protein ≥ 200 mg/24 hours by protein electrophoresis
   • If neither serum nor urine M-protein meet the criteria above, then kappa or lambda serum FLC must be ≥10 mg/dL accompanied by an abnormal kappa to lambda ratio (<0.26 or >1.65) (Serum FLC should only be used for patients without measurable serum or urine M-protein spike.)
   • If neither of the above criteria are met, the presence of plasmacytomata measurable radiographically (CT, PET or MRI) or by direct measurement.

3. Have relapsed or refractory disease after two or more prior treatment lines, each of which may have consisted of either single or multiple regimens. The investigators will ensure that patients have had the benefit of standard treatments before considering the SNS01-T clinical trial.

4. Be at least 2 weeks beyond the last therapy and have recovered from acute toxicities of prior therapies

5. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

6. Have life expectancy of at least 3 months

7. Be ≥18 years of age and willing to provide written informed consent

8. For women and men of childbearing potential, have used effective contraceptive methods for at least 4 weeks prior to dosing and agree to continue using such methods during the study, and for at least 4 weeks after completing the study

9. For women of childbearing potential, have a negative serum pregnancy test within 24 hours before the initiation of SNS01-T therapy

10. Have an absolute neutrophil count >1,000/mm3

11. Have a platelet count >75,000/mm3

12. Have total bilirubin <2.0 mg/dL

13. Have aspartate aminotransferase and alanine aminotransferase <3 times the upper limit of normal

14. Have serum creatinine ≤3 times the upper limit of normal

15. Have hemoglobin ≥8.0 g/dL

Exclusion Criteria

1. Have presence of nonsecretory myeloma
2. Have an indolent lymphoma such as follicular lymphoma unless the disease is rapidly progressing
3. Requires renal dialysis
4. Have New York Heart Association Class III-IV heart failure classification
5. Have CNS or leptomeningeal disease
6. Have an active infection or serious comorbid medical condition
7. Be receiving other concurrent anticancer agents or therapies
8. Be receiving other concurrent investigational therapies or have received investigational therapies within 4 weeks of screening or 5 half-lives, if known, whichever is shorter
9. Be eligible to receive any other standard therapy available that is known to extend life expectancy
10. Be currently receiving steroids unless equivalent to 20 mg of prednisone or less
11. Be receiving or have received heparin therapeutically within two days before and after treatment with SNS01-T
12. Be pregnant or nursing

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cohort 1	SNS01-T	0.0125 mg/kg
Cohort 3	SNS01-T	0.2 mg/kg
Cohort 2	SNS01-T	0.05 mg/kg
Cohort 4	SNS01-T	0.375 mg/kg

Primary Outcome Measures

Name	Time	Method
Safety and tolerability	Week 6	Safety and Tolerability assessed by frequency, severity, and duration of treatment-related adverse events, changes in vitals signs, physical exams and lab values

Secondary Outcome Measures

Name	Time	Method
Profile of pharmacokinetics	0.5 hours pre-dose and 0.5, 2, 6 and 24 hours post-dose	Cmax, area under curve, Tmax. Performed on Weeks 1, 3, 6, 10, 14, 18
Explore tumor response	Weeks 3 and 6, and monthly during a 24-week follow-up period	IMWG criteria, changes in M-protein, etc. for myeloma and plasma cell leukemia; Lymphoma response criteria, CT/PET scans for B cell lymphoma

Trial Locations

Locations (7)

Unversity of Cape Town - Groote Schuur Hospital; 🇿🇦 Cape Town, South Africa

Pretoria East Hospital; 🇿🇦 Pretoria, South Africa

Hackensack University Medical Center; 🇺🇸 Hackensack, New Jersey, United States

The University of Arkansas for Medical Sciences; 🇺🇸 Little Rock, Arkansas, United States

West Virginia University Mary Babb Randolf Cancer Center; 🇺🇸 Morgantown, West Virginia, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Fred Hutchinson Cancer Research Center/University of Washington Medical Center; 🇺🇸 Seattle, Washington, United States